Idorsia veröffentlicht Ankündigung der ordentlichen Generalversammlung 2020

Janssen announces submission of New Drug Application to the U.S. FDA for ponesimod for treatment of adults with relapsing multiple sclerosis

Janssen submits European Marketing Authorization Application for ponesimod for treatment of adults with relapsing multiple sclerosis

Idorsia gibt Finanzergebnisse für 2019 bekannt – deutlicher Fortschritt bei klinischen Programmen – erste Schlüsselergebnisse in Reichweite

Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy

Idorsia and Mochida enter into a license agreement for the supply, co-development and co-marketing of daridorexant in Japan

Idorsia enters into a collaboration with Antares for the development of a novel self-administered drug-device product for selatogrel

Encouraging Phase 2 data on cenerimod – Idorsia's S1P1 receptor modulator currently investigated for SLE – presented at ACR 2019

Idorsia gibt Finanzergebnisse für die ersten neun Monate 2019 bekannt

Data on cenerimod – Idorsia's S1P1 receptor modulator – will be presented at the ACR / ARP Annual Meeting 2019

Janssen reports new head-to-head Phase 3 study data show ponesimod superiority versus Aubagio (teriflunomide) 14 mg in adults with relapsing multiple sclerosis

Phase 2 data of selatogrel, Idorsia’s highly-selective P2Y12 receptor antagonist, presented at ESC 2019

Phase 2 data of aprocitentan, Idorsia’s dual endothelin receptor antagonist, presented at ESC 2019

Clinical data on Idorsia's pipeline compounds will be presented at the European Society of Cardiology Congress 2019

Janssen reports positive top-line Phase 3 results for ponesimod in adults with relapsing multiple sclerosis

Idorsia gibt Finanzergebnisse für das erste Halbjahr 2019 bekannt

Efficacy and safety data with Idorsia's dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio

Zweite ordentliche Generalversammlung von Idorsia - Alle Anträge des Verwaltungsrates angenommen

Idorsia gibt Finanzergebnisse für das erste Quartal 2019 bekannt

Idorsia veröffentlicht Einladung zur ordentlichen Generalversammlung 2019